A new study from Johns Hopkins scientists has identified a potential way to improve the effectiveness of decitabine, a chemotherapy used to treat certain cancers. By blocking the DCTPP1 protein, researchers enhanced the drug’s ability to kill prostate cancer cells, offering a potential path toward more effective treatments.
